Inhibitory effects of SU5416, a selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, on experimental corneal neovascularization

Ophthalmic Research

Volumn 47, Issue 1, 2011, Pages 13-18

  Keskin, Uǧurcan ^a   Totan, Yüksel ^a   Karadaǧ, Remzi ^a   Erdurmuş, Mesut ^a   Aydin, Bahri ^a  

^a FATIH UNIVERSITY MEDICAL SCHOOL   (Turkey)

Author keywords

Corneal neovascularization; SU5416; VEGF 2 receptor (Flk 1 KDR) tyrosine kinase inhibitor

Indexed keywords

SEMAXANIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMICROSCOPY; CONTROLLED STUDY; CORNEA; CORNEA NEOVASCULARIZATION; DRUG EFFECT; ENZYME INHIBITION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; IMAGE ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANGIOGENESIS INHIBITORS; ANIMALS; CAUTERY; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; INDOLES; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED BALB C; PYRROLES; SILVER NITRATE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 79959229034     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000324994     Document Type: Article

References (36)

1. Azar DT: Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2006; 104: 264-302. (Pubitemid 46495064)
2. Isner JM, Asahara T: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999; 103: 1231-1236. (Pubitemid 29218292)
3. Beck L Jr, D'Amore PA: Vascular development: cellular and molecular regulation. FASEB J 1997; 11: 365-373. (Pubitemid 27193941)
4. Chang JH, Gabison EE, Kato T, et al: Corneal neovascularization. Curr Opin Ophthalmol 2001; 12: 242-249. (Pubitemid 32751680)
5. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
6. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
7. Edelman JL, Castro MR, Wen Y: Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999; 40: 1112-1123. (Pubitemid 29211448)
8. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11: 753-764. (Pubitemid 44157563)
9. Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP: Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998; 39: 18-22. (Pubitemid 28040457)
10. Philipp W, Speicher L, Humpel C: Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000; 41: 2514-2522. (Pubitemid 30624378)
11. Edelman JL, Castro MR, Wen Y: Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999; 40: 1112-1123. (Pubitemid 29211448)
12. Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B: Expression of matrix metalloproteinase-2. (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000; 70: 419-428. (Pubitemid 30658885)
13. Ogawa S, Yoshida S, Ono M, Onoue H, Ito Y, Ishibashi T, Inomata H, Kuwano M: Induction of macrophage inflammatory protein-1alpha and vascular endothelial growth factor during inflammatory neovascularization in the mouse cornea. Angiogenesis 1999; 3: 327-334. (Pubitemid 129643975)
14. Shoshani Y, Pe'er J, Doviner V, Frucht-Pery J, Solomon A: Increased expression of inflammatory cytokines and matrix metalloproteinases in pseudophakic corneal edema. Invest Ophthalmol Vis Sci 2005; 46: 1940-1947.
15. Totan Y, Aydn E, Çekiç O, Dalolu MC, Borazan M, Dalolu K, Gültek A: Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr Eye Res 2001; 23: 291-297. (Pubitemid 34161302)
16. Erdurmu M, Yac R, Ylmaz B, Hepsen IF, Turkmen C, Aydn B, Karada R: Inhibitory effects of topical thymoquinone on corneal neovascularization. Cornea 2007; 26: 715-719. (Pubitemid 47080292)
17. Murata M, Shimizu S, Horiuchi S, Taira M: Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2006; 244: 205-209.
18. Boneham GC, Collin HB: Steroid inhibition of limbal blood and lymphatic vascular cell growth. Curr Eye Res 1995; 14: 1-10.
19. Castro MR, Lutz D, Edelman JL: Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 2004; 79: 275-285. (Pubitemid 39119416)
20. Peyman GA, Kazi AA, Riazi-Esfahani M, Aydin E, Kivilcim M, Sanders DR: The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. Cornea 2006; 25: 582-585. (Pubitemid 44620104)
21. Lipman RM, Epstein RJ, Hendricks RL: Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992; 110: 405-407.
22. Joussen AM, Kruse FE, Völcker HE, Kirchhof B: Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol 1999; 237: 920-927. (Pubitemid 29484167)
23. Tommila P, Summanen P, Tervo T: Cortisone, heparin and argon laser in the treatment of corneal neovascularization. Acta Ophthalmol Suppl 1987; 182: 89-92. (Pubitemid 18028390)
24. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N: Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-4599. (Pubitemid 27441066)
25. Erdurmus M, Totan Y: Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1577-1579. (Pubitemid 47423342)
26. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390. (Pubitemid 44197628)
27. Mason JO 3rd, Nixon PA, White MF: Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2006; 142: 685-688. (Pubitemid 44442055)
28. Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L: Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol In Vitro 2006; 20: 154-162 (Pubitemid 43087699)
29. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106. (Pubitemid 29062964)
30. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM: The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 2000; 6: 4848-4858. (Pubitemid 32110429)
31. Kuenen BC, Rosen L, Smit EF, et al: Dosefinding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-1667. (Pubitemid 34260548)
32. Demetri GD, van Oosterom AT, Blackstein M, et al: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. Proc Am Soc Clin Oncol 2005; 23: 4000a.
33. Escudier B, Szczylik C, Eisen T, et al: Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc Am Soc Clin Oncol 2005; 23: 4510a.
34. LinksScott EN, Meinhardt G, Jacques C, Laurent D, Thomas AL: Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin Investig Drugs 2007; 16: 367-379. (Pubitemid 46401662)
35. Takeda A, Hata Y, Shiose S, Sassa Y, Honda M, Fujisawa K, Sakamoto T, Ishibashi T: Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor. Graefes Arch Clin Exp Ophthalmol 2003; 241: 765-772. (Pubitemid 37265820)
36. Kami J, Muranaka K, Yanagi Y, Obata R, Tamaki Y, Shibuya M: Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase. Jpn J Ophthalmol 2008; 52: 91-98. (Pubitemid 351624401)